

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

**LA THANGUE et al**

Atty. Ref.: 620-149

Continuation of 09/308,935

Group:

Serial No. (To Be Assigned)

Filed: **July 6, 2001**

Examiner:

For: **PEPTIDE ANTAGONISTS OF DP  
TRANSCRIPTION FACTORS**

\* \* \* \* \*

July 9, 2001

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

**PRELIMINARY AMENDMENT**

In order to place the above-identified application in better condition for examination, please amend the application as follows:

**IN THE ABSTRACT**

Insert the attached Abstract after the claims pages.

**IN THE CLAIMS**

5. (Amended) A variant of a polypeptide as defined in claim 1, said variant differing from the polypeptide by the presence of from 1 to 5 amino acid substitutions in the sequence of said polypeptide, said variant being capable of antagonising the heterodimerization of a DP protein with an E2F protein.

7. (Amended) A polypeptide which comprises a first portion having the amino

acid sequence of a polypeptide defined in claim 1 and a second portion, attached to the N- or C-terminus of the first portion, which comprises a sequence of amino acid not naturally contiguous to the first portion in DP-1.

10. (Amended) A pharmaceutical composition comprising a polypeptide according to claim 1 together with a pharmaceutically acceptable diluent or carrier.

12. (Amended) A polypeptide according to claim 1 for use in a method of treatment of the human or animal body.

13. (Amended) A method of inducing apoptosis in a cell which comprises introducing into said cell an effective amount of a polypeptide according to claim 1.

16. (Amended) A product comprising a polypeptide as defined in claim 1 and a cytostatic or cytotoxic agent as a combined preparation for separate or sequential use in a method of treatment of the human or animal body.

17. (Amended) A surgical stent which comprises a polypeptide as defined in claim 1 in a pharmaceutically acceptable carrier.

18. (Amended) An expression vector comprising a promoter operably linked to a sequence encoding a polypeptide as defined in claim 1.

Please add the following new claim.

-- 20. A composition according to claim 10 for use in a method of treating a human or animal body. --


**REMARKS**

The above amendments are made to place the claims in a more traditional format.

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By: \_\_\_\_\_



B.J. Sadoff  
Reg. No. 36,663

BJS:eaw  
1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

706020 24700660

**MARKED UP CLAIMS**

5. (Amended) A variant of a polypeptide as defined in [any one of claims 1 to 4] claim 1, said variant differing from the polypeptide by the presence of from 1 to 5 amino acid substitutions in the sequence of said polypeptide, said variant being capable of antagonising the heterodimerization of a DP protein with an E2F protein.

7. (Amended) A polypeptide which comprises a first portion having the amino acid sequence of a polypeptide defined in [any one of claims 1 to 6] claim 1 and a second portion, attached to the N- or C-terminus of the first portion, which comprises a sequence of amino acid not naturally contiguous to the first portion in DP-1.

10. (Amended) A pharmaceutical composition comprising a polypeptide according to [any one of the preceding claims] claim 1 together with a pharmaceutically acceptable diluent or carrier.

12. (Amended) A polypeptide according to [any one of claims 1 to 9 or a composition according to claim 10] claim 1 for use in a method of treatment of the human or animal body.

13. (Amended) A method of inducing apoptosis in a cell which comprises introducing into said cell an effective amount of a polypeptide according to [any one of claims 1 to 9] claim 1.

16. (Amended) A product comprising a polypeptide as defined in [any one of claims 1 to 9] claim 1 and a cytostatic or cytotoxic agent as a combined preparation for separate or sequential use in a method of treatment of the human or animal body.

17. (Amended) A surgical stent which comprises a polypeptide as defined in

[any one of claims 1 to 9] claim 1 in a pharmaceutically acceptable carrier.

18. (Amended) An expression vector comprising a promoter operably linked to a sequence encoding a polypeptide as defined in [any one of claims 1 to 9] claim 1.

090047-0901  
FO6040-24FO0660